Anzeige
Mehr »
Login
Freitag, 19.04.2024 Börsentäglich über 12.000 News von 689 internationalen Medien
Goldaktie: Eine Erfolgsgeschichte, die seinesgleichen sucht, startet gerade richtig durch!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESSWIRE
934 Leser
Artikel bewerten:
(0)

Premier Biomedical, Inc. President and CEO, William Hartman Discusses Company Updates Since July 2018 and Their 250:1-Split with Everett Jolly on Uptick Newswire's 'Stock Day' Podcast

JACKSON CENTER, PA / ACCESSWIRE / August 27, 2018 / Premier Biomedical, Inc. (OTCQB: BIEI) (the "Company") announced President and CEO, William A. Hartman's interview on Uptick Newswire's "Stock Day" Podcast.

Everett Jolly began the interview by welcoming back Premier Biomedical, Inc. President and CEO, William A. Hartman for a Company update since July 2018. Jolly stated that he still thinks this Company is undervalued even after their 250:1-split. Jolly asked Hartman to give his listeners information about their latest developments.

Hartman got right to the point. Premier Biomedical has recently formed an agreement with ex-Army purchasing group called "4 Your Pain." This group has taken on the task of introducing Premier Biomedical's CBD topical pain relief products to the military and to the government as an alternative to dangerous and addictive opioid pain medications. The Company's goal is to be the primary source for all pain medications for the military and the governmental agencies.

Hartman added,"What is driving the market explosion of our superior topical pain relief products is the fact that almost 200 people per day are dying from drug overdoses, and a recent study concluded that almost 70% of those people started on opioid pain medications. This is a real opioid crisis in this country."

Premier Biomedical primary focus is the manufacture and distribution of all-natural, 50-state legal, pesticide-and solvent-free hemp oil-based pain management products, including 96-hour pain relief patches, roll-on applicators, ointments, and pump sprays sold on the Company's website at www.painreliefmeds.com and at select pharmacies and doctors' offices.

Jolly wanted to know what makes the Company's products so special. Hartman indicated that it was a combination of things, including a unique formulation and products containing more much CBD than the competition. Their new line of Extra Strength "Pain-Ex II ™' products have even more CBD than the competition at market prices That means real pain relief, which is what people suffering from pain are seeking.

Premier Biomedical also has recently re-organized their industry-leading technologies in their separate Biologics Division. The Company recently placed these on-the-shelf technologies into separate centers of expertise, providing specific technology investors assurance of focused use of funds without diluting the Company's stock. The Company announced this as a win for technology investors and a win for stockholders.

Jolly asked what listeners should take away from this interview. Hartman said the biggest thing we have coming is a potential near-term joint venture, which will help expand the Company dramatically. He can't say any more because it's not finalized, but this is just a teaser for your podcast listeners.

Hartman concluded, "We're a Company about change. We're a Company about responding to the market and responding to our investors. We have experienced many challenges, but we have erupted from them even stronger than ever. I see a brilliant future for this Company!" Hartman stated that he looks forward to returning to the podcast in the near future with another exciting update.

For more information about the Company's financial details, listen to the full interview at the link below.

http://www.premierbiomedical.com/wp-content/uploads/2018/08/Uptick-Podcast-27-Aug-18.mp3

About Premier Biomedical, Inc. (BIEI):

Premier Biomedical, Inc., is in part a research-based company that primarily intends to discover and develop medical products. Our current focus is on the distribution of our pain management products. Our current pain management products are made from hemp oil extracts and include roll-on applicators, pain relief patches, creams and pump spray applicators. We also conduct research and development of proprietary drugs and techniques to target PTSD, cancer, anti-aging, multiple sclerosis and other diseases. Visit their website at www.premierbiomedical.com

Contact:

Premier Biomedical, Inc.
P.O. Box 25
Jackson Center, PA 16133
(814) 786-8849
http://www.premierbiomedical.com/
info@premierbiomedical.com
https://painreliefmeds.com/

Safe Harbor Act and Forward-Looking Statements

This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential" "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Additional information concerning these and other risk factors is contained in the Company's most recent filings with the Securities and Exchange Commission. The Company cautions readers not to place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in their expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law.

About Uptick Newswire and the "Stock Day" Podcast

Founded in 2013, Uptick Newswire is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Uptick provides companies with customized solutions to their news distribution in both national and international media outlets. Uptick is the sole producer of its "Stock Day" Podcast, which is the number one radio show of its kind in America. The Uptick Network "Stock Day" Podcast is an extension of Uptick Newswire, which recently launched its Video Interview Studio located in Phoenix, Arizona.

Investors Hangout is a proud sponsor of "Stock Day," and Uptick Newswire encourages listeners to visit the company's message board at https://investorshangout.com/

Uptick Newswire
https://upticknewswire.com/

SOURCE: Premier Biomedical, Inc.

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2018 ACCESSWIRE
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.